Indianpharma

$IpcaLab: Indian Pharma’s Next Big Breakout mover.💊 💊 💊 Ipca Labs is currently screaming "institutional accumulation." We are looking at a massive Hunt Volatility Funnel that has been tightening since mid-2025. The price action is getting squeezed into a very narrow range, which historically acts like a coiled spring. A breakout above the 1,561–1,600 pivot zone could trigger a massive momentum run. Why the "Alpha" is in Ipca right now (Growth Drivers): Regulatory Tailwinds: With recent manufacturing clearances and a clean bill of health fo

Zydus Lifesciences $ZYDUSLIFE will reward the stackers!💊🚀 💊🚀 💊🚀 The Technical Thesis: Breaking the Decade-Long Diagonal The daily chart shows a massive falling wedge/diagonal resistance that has suppressed price action since 2024. The Breakout: The recent push above ₹956 is a high-volume confirmation that the trend has reversed. Volume Gap: between ₹1080 and ₹1150. Once the stock clears the T1 ($999) and T2 ($1150) levels, there is very little historical "supply" to stop a run toward the Full Log Target of ₹1544. 5 Bullish Drivers for New ATHs

Is $Gland Pharma the next multi-bagger breakout? 💊💊💊 The chart say's yes. Institutional Alpha Unlocked! While the crowd is distracted, Gland Pharma has been quietly building one of the cleanest setups on the NSE. We are looking at a classic "Bottoming Out" phase characterised by three distinct rising valleys, each one shallower than the last. This indicates that sellers are exhausted and buyers are stepping in at higher levels every time. Why this is "Free Alpha" The "Ultimate" Breakout Level: The chart identifies the critical pivot at

Nifty Pharma Index – Multi-Year Breakout Setup Nifty Pharma appears to be resolving a multi-year consolidation within an ascending triangle, with price now testing a key supply zone near prior highs. The structure suggests accumulation over ~18–24 months, followed by a potential expansion phase. This is not just a technical breakout attempt—sector fundamentals are turning supportive, driven by a shift toward high-margin specialty products, improving export visibility, and resilient domestic demand in chronic therapies. A confirmed breako

NIFTY PHARMA It is showing the strength. Generally in weak market Pharma & FMCG show strength. Any follow up here will give good upside in no time. Just keep strong counters in watchlist or one may try with heavily beaten up stocks from the sectors. Heavily beaten down will give far more risk adjusted returns than stock which are strong but to catch the falling knife is really an art. So try with strong one first then slowly start for catching falling knife

Indian Pharma Sector Stocks - It Is All About Rotation So what's ailing Indian Pharma sector stocks? Those who really looked like on steroids are suddenly behaving like they have swallowed over dose of laxatives. Few environmental changes are to blame, 1. ) Rotation Yes folks, those who rode it from Rs. 100 a stock to 1500 are taking profit and putting that money to some other sector where they believe market it going to perform well. Look at Reliance, a single stock has gobbled up many thousand crore in its rally. From where that money came to b

Mangalam Drugs Long update The wave 2 correction in Mangalam Drugs seems to have become a bit complex. Now it appears to be at a structural support. Also there is 61% Fib support. So it's likely that the up move could start. Any move below wave 1 low would negate this setup.

by tushargupta1991